Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | APP | P05067 | 3/20 | 0.37 |
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18931456 | 0.94 | CYP3A4 (0.34) | CYP3A4IDO1APPSPHK2SPHK1 | |
| SCHEMBL9004469 | 0.87 | GFER (0.36) | CYP3A4 | |
| SCHEMBL8073139 | 0.86 | SPHK2 (0.40) | CYP3A4IDO1APPSPHK2SPHK1 | |
| SCHEMBL6285109 | 0.85 | GFER (0.41) | CYP3A4 | |
| SCHEMBL8072128 | 0.85 | SPHK2 (0.45) | SPHK2SPHK1SIGMAR1 | |
| SCHEMBL8072635 | 0.83 | SPHK2 (0.48) | SPHK2SPHK1 | |
| SCHEMBL8062890 | 0.83 | SPHK2 (0.48) | SPHK2SPHK1 | |
| SCHEMBL8073049 | 0.83 | SPHK2 (0.48) | SPHK2SPHK1 | |
| SCHEMBL8070908 | 0.83 | SPHK2 (0.48) | SPHK2SPHK1 | |
| SCHEMBL8854472 | 0.80 | HRH3 (0.41) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| EP-3442045-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, AND SOLAR BATTERY MODULE AND SENSOR PROVIDED WITH SAME | Sumitomo Chemical Company, Limited (JP) | 2019-02-13 | — | — | EP | disclosed |
| US-9777116-B2 | Porous/nanoporous PHT | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170173170-A1 | METHODS AND MATERIALS FOR THERAPEUTIC DELIVERY | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2017-06-22 | — | — | US | disclosed |
| US-6063940-A | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-05-16 | — | — | US | disclosed |
| US-5637736-A | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-06-10 | — | — | US | disclosed |
| EP-0637580-A1 | Process for preparing 1-bromoalkylbenzene derivatives and intermediates thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1995-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | CYP3A4 3758/4885IDO1 1457/4885APP 2634/4885 |
| US-20170173170-A1 | METHODS AND MATERIALS FOR THERAPEUTIC DELIVERY | PAICS, PHPT1, MAPT | CYP3A4 3225/4885IDO1 2176/4885APP 392/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | CYP3A4 4098/4885IDO1 1659/4885APP 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.